Madrigal Pharmaceuticals vs Insulet

Madrigal Pharmaceuticals (MDGL), health care, and Insulet (PODD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Insulet is worth $10.1B on the stock market and Madrigal Pharmaceuticals $9.8B: Insulet is valued at 3% more. Madrigal Pharmaceuticals's operating margin in its latest fiscal year was -31.3% and Insulet's 17.5%. Over the past year Madrigal Pharmaceuticals's share price has moved -24.2% and Insulet's -56.4%.

Key facts

Madrigal Pharmaceuticals market value
$9.8B
Insulet market value
$10.1B
Insulet P/E
23.7
Madrigal Pharmaceuticals revenue
$958.4MFY to 2025-12-31
Insulet revenue
$2.7BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Madrigal Pharmaceuticals vs Insulet: every measure side by side
Measure Madrigal Pharmaceuticals Insulet
SectorHealth CareHealth Care
Country United States United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$9.8Blower$10.1Bhigher
Revenue$958.4Mlower$2.7Bhigher
Earnings-$288.3Mlower$247.1Mhigher
Employees915lower5,400higher
Total assets$1.3Blower$3.2Bhigher
Valuation
P/E—23.7
P/S10.2higher3.7lower
P/B15.6higher6.4lower
Dividend yield0.00%0.00%
Profitability
Operating margin-31.3%lower17.5%higher
Balance sheet
Net assets$602.7Mlower$1.5Bhigher
Total liabilities$656.9Mlower$1.7Bhigher
Total debt$339.9Mlower$949.2Mhigher
Cash on hand$198.7Mlower$716.1Mhigher
Price change
Today-0.46%lower+0.03%higher
1 year-24.2%higher-56.4%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Madrigal Pharmaceuticals only (5)

Insulet only (1)

Percentages are each holding's share of that investor's reported portfolio. Who owns MDGL · Who owns PODD

Further comparisons

Learn

Questions and answers

Which is bigger, Madrigal Pharmaceuticals or Insulet?

By market value, Insulet is the larger: $10.1B against $9.8B for Madrigal Pharmaceuticals. By revenue in its latest fiscal year, Insulet is the larger: $2.7B against $958.4M for Madrigal Pharmaceuticals.

Which has the higher operating margin?

Insulet: 17.5%, against -31.3% for Madrigal Pharmaceuticals. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has the higher dividend yield?

Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.

Which has more debt?

Insulet: $949.2M, against $339.9M for Madrigal Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Madrigal Pharmaceuticals and Insulet?

None of the tracked superinvestors holds both in their latest 13F filing. 5 hold Madrigal Pharmaceuticals and 1 holds Insulet.

Cite this page

Funkfolio, “Madrigal Pharmaceuticals vs Insulet”, data as of 17 November 2026. https://funkfolio.com/compare/mdgl-vs-podd

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.